This pharmaceutical company joins hands with scientific research institutions to jointly research and develop new Chinese medicines

[Pharmaceutical Network Enterprise News] On August 17, Panlong Pharmaceutical issued an announcement that the company recently signed a "Technology Development (Cooperation) Contract" with the Shaanxi Academy of Traditional Chinese Medicine
.

The two parties intend to jointly participate in the research and development of the new Chinese medicine "Qingwen Hufei Granules" for the treatment of Qi deficiency and lung heat type cold (or influenza)
.

The technical content of the cooperation between the two parties requires: complete the clinical pre-trial, pharmaceutical research, pharmacodynamics, safety evaluation, and clinical research of a new traditional Chinese medicine (Qingwen Hufei Granule) for the treatment of qi deficiency and lung heat type cold (or influenza), and complete the development of the new traditional Chinese medicine.
Production registration, obtained the drug registration certificate issued by the State Drug Administration
.

According to the main content of the agreement, Shaanxi Academy of Traditional Chinese Medicine is responsible for formulating and carrying out a clinical pre-trial program on "Qingwen Hufei Granules" in the treatment of cold (or influenza) caused by Qi deficiency and lung heat, and actively cooperates with Panlong Pharmaceutical to carry out "Qingwen Hufei Granules" Pre-clinical research work on new drugs for Hufei Granules; after obtaining the clinical approval, assist Panlong Pharmaceutical in the collection of clinical trial data such as practical clinical trials (PCT) or randomized controlled clinical trials (RCT) and provide corresponding technical support
.

Panlong Pharmaceutical Co.
, Ltd.
is responsible for building a technical team for the transformation of the hospital preparation "Qingwen Hufei Granules" into new traditional Chinese medicines; Influenza) clinical pre-trial program to confirm and so on
.

Both parties confirmed that Panlong Pharmaceutical owns the ownership of the preclinical research materials of "Qingwen Hufei Granules", and owns the relevant trade secrets and intellectual property rights arising from the subsequent development of the product
.

Regarding the impact of this cooperation, Panlong Pharmaceutical stated that the joint development through the platform of the company's convertible bond investment project "Centralized Preparation Center for Preparations in the Hospital" aims to improve the company's competitiveness and sustainable profitability.
Strategic layout plays a positive role
.

 　　It is understood that in-hospital preparations are the embodiment of the characteristics of traditional Chinese medicine and an important source for the creation of new traditional Chinese medicines.
They are prescriptions from many years of clinical practice or classic prescriptions of traditional Chinese medicine.
They have the advantages of exact curative effect, small side effects and low price, and have huge market potential
.

 　　In the 2021 annual report, Panlong Pharmaceutical mentioned that in the field of traditional Chinese medicine, the company takes promoting the development of "Qin Yao" as its own responsibility, focuses on the overall situation of physical operation and capital operation, and focuses on new traditional Chinese medicine, hospital preparations, formula granules, classic The breakthrough in the development of Mingfang is currently underway
.

 　　In fact, the cooperation between Panlong Pharmaceutical and Shaanxi Institute of Traditional Chinese Medicine has already started.
In March this year, Panlong Pharmaceutical announced the issuance of convertible bonds with a scale of 276 million yuan.
Among them, the funded investment in the construction project of a centralized preparation center for medical institutions in Shaanxi Province , the total investment is 151 million yuan, because of the huge market development potential of the preparations in the hospital
.

At that time, Panlong Pharmaceutical had signed a strategic cooperation agreement with Shaanxi Institute of Traditional Chinese Medicine, and planned to jointly develop "Qingwen Hufei Granules" with the platform of "Centralized Distribution Center for In-Hospital Preparations" through this convertible bond fundraising project.

.

And "Qingwen Hufei Granules" is an in-hospital preparation of traditional Chinese medicine declared and approved by the Shaanxi Academy of Traditional Chinese Medicine
.

 　　According to the data, Panlong Pharmaceutical is an enterprise integrating GAP cultivation of medicinal materials, drug production, research and development, sales and pharmaceutical logistics as its core industries.
, digestion, tonic, heat-clearing and detoxification, pediatrics, gynecology, hepatobiliary and other functional categories, a strong product lineup of more than 100 specifications
.

 　　Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.